Ying Huang, Legend Biotech CEO
February 28, 2022 05:48 PM ESTUpdated March 1, 07:06 AM
Pharma
FDA+

'We are ready to go': FDA OKs J&J and Leg­end's BC­MA CAR-T, set­ting stage for show­down with Bris­tol My­ers

Nicole DeFeudis

Editor

Move over, Bris­tol My­ers Squibb. Af­ter de­lay­ing their de­ci­sion by three months to re­view new in­for­ma­tion, the FDA has cleared John­son & John­son and Leg­end …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times